FDA NDA · NDA206040

LAMIVUDINE; ZIDOVUDINE; EFAVIRENZ

Sponsor: MYLAN LABS LTD

APPLICATION

NDA206040

TYPE

NDA

ROUTE

ORAL

DOSAGE FORM

TABLET

MARKETING STATUS

None (Tentative Approval)

Products

LAMIVUDINE; ZIDOVUDINE; EFAVIRENZNone (Tentative Approval)

LAMIVUDINE 150MG, ZIDOVUDINE 300MG, EFAVIRENZ 600MG · TABLET · ORAL

2014-09-04Type 4 - New Combination · Original · standard — Letter ↗TA

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.